About
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
Top Deals
SOLD
Share this deal
Florida | Industrial | PPSF: $234
09/17/2025
Focus
Sale
Markets
FAQs
Lupin Research Inc. has financed 1 deal.
Lupin Research Inc.'s most recent deal was on September 17, 2025.
Lupin Research Inc.'s largest deals include a sale of $14,600,000.00 for 12095 Northwest 39th Street.
Member since: September 2025
Deals
Transaction Type
Asset Type
State
Sort By
SOLD
Vinita Gupta Of Lupin Research Inc. Acquires Industrial Facility In Coral Springs For $14.6M From Mitsuya Kishida
$234/SF
12095 Northwest 39th Street, Coral Springs, FL
FLCRE
Sep 17, 2025